Founder on board


Founder on board

25.05.2016 - Frode Marc Bohan has been reelected as Chairman of the Board of Directors for Norwegian Vitamin K2 expert NattoPharma ASA. He will continue to chair the board for the next two years.

Bohan founded NattoPharma in 2004. He later founded NoLabel and NutriCon, a nutraceutical and pharmaceutical communications companyl, respectively. Bohan is also a substantial Shareholder of Eqology ASA, and the chairman of the Board of directors at ImmunoPharma AS.

Simultaneously with Bohan’s reelection as chair, the Board of Directors has been extended by two members: Stefan Halldén and Annette Elmqvist.


28.03.2016 Georges Tabary is taking over the lead of Paris-based BioAxial as CEO and president. BioAxial develops imaging instruments for fluorescence microscopy that allow extended imaging of live cells with a very high resolution.

© BioAxial / ALA

Tabary comes to BioAxial from Mauna Kea Technologies, where he was vice president of strategic accounts. Prior to that, he spent seven years with Leica Microsystems of Danaher Group, where he led the European surgical microscopy and histopathology businesses. He was also president of Leica Microsystèmes SAS, and before that, served as vice president and general manager for Intuitive Surgical Europe. 


23.03.2016 Renowned stem cell expert Fiona Watt has joined the board of the Cell and Gene Therapy Catapult, a UK organisation dedicated to the growth of the UK cell and gene therapy industry. In February, Watt had been announced as the winner of the 2016 FEBS | EMBO Women in Science Award.

© King’s College London

Watt helped establish the Cancer Research UK (CRUK) Cambridge Research Institute and the Wellcome Trust Centre for Stem Cell Research in Cambridge. She served both as Deputy Director  until 2012, when she took over as Director of the Centre for Stem Cells and Regenerative Medicine at King's College, London. She leads the UK Human Induced Pluripotent Stem Cell Initiative. 

She is one of three new Non-Executive Directors on the Board of the UK organisation, the others being Susan Foden and Steven Chatfield. 


21.03.2016 The Board of Directors of ASEBIO, the Spanish Association of Biotechnology Companies, has appointed Ion Arocena Velez as its new General Managzer. Arocena is also a partner at AS Law Biotech Desk and a partner at Life Science VC company Suanfarma Biotech.


Arocena holds a bachelor degree in biology from Universidad Complutense de Madrid as well as an economy MBA from EOI Business School. He previously worked for Genoma España. He is on the board of Vivia Biotech. 


17.03.2016 The Brain Prize, the most valuable research prize for brain science, went to Edinburgh neuroscientist Richard Morris and two of his colleagues. Morris received the €1m award in recognition of his work to understand the mechanisms of memory.

© Centre for Cognitive and Neural Systems, University of Edinburgh

Morris shares the Brain Prize with fellow neuroscientists Tim Bliss and Graham Collingridge. Together, the researchers worked to understand the brain mechanisms that underpin our ability to learn and remember. Their discoveries have paved the way to better understanding of complex brain conditions such as autism, schizophrenia, depression, chronic pain, epilepsy and addiction.

Morris, who has received a number of prizes and awards, is professor of neuroscience at the University of Edinburgh as well as Honorary Associate of the Instituto de Neurociencias in Alicante. 

 Born 27 June 1948 in the United Kingdom, received his BA in Natural Sciences from the University of Cambridge and his D.Phil from Sussex University. He is Professor of Neuroscience at the University of Edinburgh and an Honorary Associate of the Instituto de Neurociencias in Alicante.


14.03.2016 Håkan Wickholm is taking over as CEO of Norwegian cancer immunotherapy specialist Lytix Biopharma. Wickholm succeeds Unni Hjelmaas, who had led the company for four years.

© Lytix Biopharma

Previously, Wickholm was Lytix’ head of Business Development, a role he will continue to hold. The appointment reflects the company’s plans to increase its focus on business development.

Before joining Lytix, Wickholm worked at AstraZeneca, where he last held the position of Regional Business Development for Central and Eastern Europe, the Middle East and Africa. He holds a BSc in Businss Administration and Economics from Uppsala University and a Postgraduate diploma in Business Management and Finance from Warwick Business School, UK.


10.03.2016 Orphan drug developer Onxeo has elected Joseph Zakrzewski Chairman of the Board of Directors. He also sits on the Board publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals and Insulet Corporation.

© Onxeo

Zakrzewksi has worked in the pharma industry for almost two decades. He was Chairman and CEO of US-Irish Amarin Pharmaceuticals, which develops cardiovascular drugs based on Omega 3. He also served as a Venture Partner with healthcare investment firm Orbimed and was CEO and President of Xcellerex, a company focusing on commercialising its proprietary manufacturing tech for biotherapeutics and vaccines. Zakrzewski received a BS in Chemical Engineering in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.

Zakrzewski replaced Patrick Langlois, who resigned. Onxeo also appointed oncology experts Jean-Pierre Kinet and Jean-Pierre Bizzari Observers to the Board of Directors.


07.03.2016 Belgian cell therapy developer Celyad has appointed Richard Mountfield as as Vice President of Global Regulatory Affairs in early February. Mountfield has an extensive experience in regulatory affairs and drug development.

© Celyad

Before joining Celyad, Mountfield held positions in Europe and the US, working for notable companies such as Novartis, Roche, Novo Nordisk and Boehringer Ingelheim. Most recently, he was the global regulatory lead responsible for developing and implementing strategies for a multi-indication oncology programme within Novartis. He holds a biochemistry PhD from Aberystwyth University. 


03.03.2016 Having spent the almost 30 years of her working life with the Swiss pharma giant, Roche’s Head of Group Human Resources Silvia Ayyoubi is retiring. She held this position and was also a member of the Corporate Executive Committee since 2008.

© Roche

Ayyoubi joined Roche in 1987 as Public Relations Manager and advanced through the ranks in Public Relations and later Human Resources. Before Roche, Ayyoubi worked at the Swiss Ministry of Foreign Affairs as well as Effifreight. She holds a diploma in commercial economics.

Roche has appointed Cristina Wilbur to succeed Silvia Ayyoubi as Head of Group Human Resources and member of the Corporate Executive Committee.


01.03.2016 Acclaimed cardiologist and geneticist Sekar Kathiresan is taking over the chair of the newly established Scientific Advisory Board of Genomics plc. The Oxford-based company develops algorithms and analytical software to analyse and interpret genomic data.

© Genomics

Kathiresan, who received his M.D. from Harvard Medical School in 1997, is now the director of preventive cardiology at Massachusetts General Hospital (MGH) Heart Center. He is also an associate member in the Broad Institute’s Programme in Medical and Population Genetics, and an associate professor of medicine at Harvard Medical School. He is part of an expert panel that was formed to assist US president Barrack Obama’s Precision Medicine Initiative.


29.02.2016 Systems biology pioneer Jens Nielsen is the recipient of this year’s Novozymes Prize. The Novo Nordisk Foundation annually donates DKK3m (€400.000) to the awardee of the prize, which aims to raise awareness of basic and applied biotechnology research.

© Novo Nordisk Foundation

Nielsen is a professor at Chalmers University of Technology in Göteborg, Sweden and Chief Scientific Officer of the Novo Nordisk Foundation Center for Biosustainability in Hørsholm, Denmark.

Nielsen receives the award for his “outstanding efforts over many years in developing systems biology.” Søren Molin, chair of the Novozymes Prize Committee, said: “Jens Nielsen has unique knowledge of the most important aspects of the new systems biology – mathematics, reaction and fermentation science, data integration and modern microbial genetics. He has been able to combine and use this knowledge creatively and intuitively to contribute massively to the basic understanding of the physiology of microorganisms and how this is regulated.”

Vorherige Seite2/35Nächste Seite


Current issue

All issues

Product of the week


Stock list

All quotes


  • PLETHORA (UK)3.38 GBP12.67%
  • ZEALAND PHARMA (DK)130.50 DKK11.06%


  • BIOFRONTERA (D)2.84 EUR-4.70%
  • CHRONTECH PHARMA (S)0.34 SEK-2.86%
  • PHOTOCURE (N)41.50 NOK-2.35%


  • GALAPAGOS (B)52.23 EUR29.6%
  • NICOX (F)10.89 EUR26.8%
  • RENEURON (UK)3.70 GBP26.7%


  • BIONOR PHARMA (N)0.70 NOK-23.1%
  • BIOCARTIS GROUP NV (B)8.32 EUR-23.0%
  • MOBERG PHARMA (S)38.70 SEK-23.0%


  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)29.50 SEK1992.2%
  • NICOX (F)10.89 EUR482.4%


  • BB BIOTECH (D)44.62 EUR-84.3%
  • BIOTEST (D)17.10 EUR-77.5%

No liability assumed, Date: 25.05.2016


All Events



Biomedica 2016

Basel (CH)

Chemspec Europe 2016